Skip to main content

Table 2 Time to treatment failure on AAP across different patient subgroups based on the period of time between castration and mCRPC diagnosis

From: Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Time between bilateral orchiectomy or ADT treatment and mCRPC diagnosis

Percentile

Estimate of Time to Treatment Failure on AAP (months) (95% CI)

Logrank Test p-value

< 12 months (n = 87)

75

11.9 (10.0–14.0)

< 0.0001

50

7.9 (6.6–8.9)

25

4.4 (2.3–5.8)

≥12 months (n = 338)

75

19.7 (16.3–21.2)

50

11.5 (10.0–12.1)

25

5.6 (5.0–6.8)